{"id":22990,"date":"2024-03-06T16:02:46","date_gmt":"2024-03-06T15:02:46","guid":{"rendered":"https:\/\/ggba.swiss\/?p=22990"},"modified":"2024-03-06T16:02:47","modified_gmt":"2024-03-06T15:02:47","slug":"arga-medtech-secures-eur-54-million-towards-its-atrial-fibrillation-treatment","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/arga-medtech-secures-eur-54-million-towards-its-atrial-fibrillation-treatment\/","title":{"rendered":"Arg\u00e1 Medtech secures EUR 54 million towards its atrial fibrillation treatment"},"content":{"rendered":"\n<p>Headquartered at the <a href=\"https:\/\/www.biopole.ch\/\">Biop\u00f4le<\/a> life sciences campus in Lausanne, with additional operations in San Diego, California, <a href=\"https:\/\/argamedtech.com\/\">Arg\u00e1 Medtech<\/a> is at the forefront of developing next-generation treatments for cardiac arrhythmias, specifically atrial fibrillation (AF). The company&#8217;s Coherent Sine-Burst Electroporation\u2122 (CSE\u2122) technology represents a significant advancement in the field of minimally invasive surgical interventions for treating AF.<\/p>\n\n\n\n<p>Arg\u00e1 Medtech&#8217;s novel CSE\u2122 ablation system offers electrophysiologists an unparalleled capability to safely and efficiently treat various regions of the heart using a versatile, all-in-one catheter. This technology not only ensures a safer treatment method by minimizing the risk of thermal injuries to surrounding tissues but also simplifies the procedure, reducing the overall treatment time and associated costs.<\/p>\n\n\n\n<p>The company recently announced the successful closure of a EUR 54 million Series B funding round. This significant financial milestone, led by a consortium of investors including Advent Life Sciences (UK), Earlybird Health (Germany), Gilde Healthcare (the Netherlands), and an undisclosed strategic investor, aims to propel the clinical studies of Arg\u00e1 Medtech&#8217;s innovative cardiac ablation system in both the United States and the European Union.<\/p>\n\n\n\n<p>David Neale, CEO of Arg\u00e1 Medtech, expressed his gratitude for the investors&#8217; support, highlighting their shared vision of revolutionizing AF ablation treatment. The funds will primarily facilitate the execution of an Investigational Device Exemption (IDE) study in the US and a CE Mark study in the EU, paving the way for broader accessibility of their CSE\u2122 Pulsed Field Ablation (PFA) system.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">A safer, more precise alternative for stroke patients<\/h4>\n\n\n\n<p>The funding also supports the expansion of Arg\u00e1 Medtech&#8217;s operations in San Diego, anticipating the increase in clinical activities in the United States. Furthermore, this Series B round builds on the company&#8217;s momentum following a 48-patient first-in-human study in Europe, which showcased the platform&#8217;s efficacy in treating AF.<\/p>\n\n\n\n<p>Atrial fibrillation, as the most common cardiac arrhythmia globally, significantly increases the risk of stroke among patients. The traditional thermal energy ablation methods, while effective, carry higher risks compared to PFA energy delivery. Arg\u00e1 Medtech&#8217;s solution aims to provide a safer, more precise alternative for the millions affected by this condition.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Arg\u00e1 Medtech, a pioneer in pulsed field ablation technology, has successfully completed its EUR 54 million Series B financing round.<\/p>\n","protected":false},"author":6,"featured_media":22991,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[894,963,926,902,901],"class_list":["post-22990","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-financing","tag-medical-devices","tag-medtech","tag-personalized-medicine","tag-technology-park"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Arg\u00e1 Medtech secures EUR 54M for its atrial fibrillation treatment<\/title>\n<meta name=\"description\" content=\"Arg\u00e1 Medtech, a pioneer in pulsed field ablation technology, has successfully completed its EUR 54 million Series B financing round.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/arga-medtech-secures-eur-54-million-towards-its-atrial-fibrillation-treatment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Arg\u00e1 Medtech secures EUR 54M for its atrial fibrillation treatment\" \/>\n<meta property=\"og:description\" content=\"Arg\u00e1 Medtech, a pioneer in pulsed field ablation technology, has successfully completed its EUR 54 million Series B financing round.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/arga-medtech-secures-eur-54-million-towards-its-atrial-fibrillation-treatment\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-06T15:02:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-06T15:02:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Arga-Medtech-1180x811-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/en\/arga-medtech-secures-eur-54-million-towards-its-atrial-fibrillation-treatment\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/en\/arga-medtech-secures-eur-54-million-towards-its-atrial-fibrillation-treatment\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Arg\u00e1 Medtech secures EUR 54 million towards its atrial fibrillation treatment\",\"datePublished\":\"2024-03-06T15:02:46+00:00\",\"dateModified\":\"2024-03-06T15:02:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/arga-medtech-secures-eur-54-million-towards-its-atrial-fibrillation-treatment\/\"},\"wordCount\":363,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/arga-medtech-secures-eur-54-million-towards-its-atrial-fibrillation-treatment\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Arga-Medtech-1180x811-1.jpeg\",\"keywords\":[\"Financing\",\"Medical Devices\",\"Medtech\",\"Personalized Medicine\",\"Technology Park\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/en\/arga-medtech-secures-eur-54-million-towards-its-atrial-fibrillation-treatment\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/en\/arga-medtech-secures-eur-54-million-towards-its-atrial-fibrillation-treatment\/\",\"url\":\"https:\/\/ggba.swiss\/en\/arga-medtech-secures-eur-54-million-towards-its-atrial-fibrillation-treatment\/\",\"name\":\"Arg\u00e1 Medtech secures EUR 54M for its atrial fibrillation treatment\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/arga-medtech-secures-eur-54-million-towards-its-atrial-fibrillation-treatment\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/arga-medtech-secures-eur-54-million-towards-its-atrial-fibrillation-treatment\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Arga-Medtech-1180x811-1.jpeg\",\"datePublished\":\"2024-03-06T15:02:46+00:00\",\"dateModified\":\"2024-03-06T15:02:47+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Arg\u00e1 Medtech, a pioneer in pulsed field ablation technology, has successfully completed its EUR 54 million Series B financing round.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/en\/arga-medtech-secures-eur-54-million-towards-its-atrial-fibrillation-treatment\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/en\/arga-medtech-secures-eur-54-million-towards-its-atrial-fibrillation-treatment\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ggba.swiss\/en\/arga-medtech-secures-eur-54-million-towards-its-atrial-fibrillation-treatment\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Arga-Medtech-1180x811-1.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Arga-Medtech-1180x811-1.jpeg\",\"width\":1180,\"height\":811,\"caption\":\"Arg\u00e1 Medtech's technology assesses the safety and effectiveness of coherent sine wave electroporation in patients with atrial fibrillation. | \u00a9 Arg\u00e1 Medtech\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/en\/arga-medtech-secures-eur-54-million-towards-its-atrial-fibrillation-treatment\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Arg\u00e1 Medtech secures EUR 54 million towards its atrial fibrillation treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Arg\u00e1 Medtech secures EUR 54M for its atrial fibrillation treatment","description":"Arg\u00e1 Medtech, a pioneer in pulsed field ablation technology, has successfully completed its EUR 54 million Series B financing round.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/arga-medtech-secures-eur-54-million-towards-its-atrial-fibrillation-treatment\/","og_locale":"en_US","og_type":"article","og_title":"Arg\u00e1 Medtech secures EUR 54M for its atrial fibrillation treatment","og_description":"Arg\u00e1 Medtech, a pioneer in pulsed field ablation technology, has successfully completed its EUR 54 million Series B financing round.","og_url":"https:\/\/ggba.swiss\/en\/arga-medtech-secures-eur-54-million-towards-its-atrial-fibrillation-treatment\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2024-03-06T15:02:46+00:00","article_modified_time":"2024-03-06T15:02:47+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Arga-Medtech-1180x811-1.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pierre-Yves Oehrli","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/arga-medtech-secures-eur-54-million-towards-its-atrial-fibrillation-treatment\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/arga-medtech-secures-eur-54-million-towards-its-atrial-fibrillation-treatment\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Arg\u00e1 Medtech secures EUR 54 million towards its atrial fibrillation treatment","datePublished":"2024-03-06T15:02:46+00:00","dateModified":"2024-03-06T15:02:47+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/arga-medtech-secures-eur-54-million-towards-its-atrial-fibrillation-treatment\/"},"wordCount":363,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/en\/arga-medtech-secures-eur-54-million-towards-its-atrial-fibrillation-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Arga-Medtech-1180x811-1.jpeg","keywords":["Financing","Medical Devices","Medtech","Personalized Medicine","Technology Park"],"articleSection":["Life sciences"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/en\/arga-medtech-secures-eur-54-million-towards-its-atrial-fibrillation-treatment\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/arga-medtech-secures-eur-54-million-towards-its-atrial-fibrillation-treatment\/","url":"https:\/\/ggba.swiss\/en\/arga-medtech-secures-eur-54-million-towards-its-atrial-fibrillation-treatment\/","name":"Arg\u00e1 Medtech secures EUR 54M for its atrial fibrillation treatment","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/arga-medtech-secures-eur-54-million-towards-its-atrial-fibrillation-treatment\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/arga-medtech-secures-eur-54-million-towards-its-atrial-fibrillation-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Arga-Medtech-1180x811-1.jpeg","datePublished":"2024-03-06T15:02:46+00:00","dateModified":"2024-03-06T15:02:47+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Arg\u00e1 Medtech, a pioneer in pulsed field ablation technology, has successfully completed its EUR 54 million Series B financing round.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/arga-medtech-secures-eur-54-million-towards-its-atrial-fibrillation-treatment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/arga-medtech-secures-eur-54-million-towards-its-atrial-fibrillation-treatment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ggba.swiss\/en\/arga-medtech-secures-eur-54-million-towards-its-atrial-fibrillation-treatment\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Arga-Medtech-1180x811-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Arga-Medtech-1180x811-1.jpeg","width":1180,"height":811,"caption":"Arg\u00e1 Medtech's technology assesses the safety and effectiveness of coherent sine wave electroporation in patients with atrial fibrillation. | \u00a9 Arg\u00e1 Medtech"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/arga-medtech-secures-eur-54-million-towards-its-atrial-fibrillation-treatment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"Arg\u00e1 Medtech secures EUR 54 million towards its atrial fibrillation treatment"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/22990","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=22990"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/22990\/revisions"}],"predecessor-version":[{"id":22994,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/22990\/revisions\/22994"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/22991"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=22990"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=22990"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=22990"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}